SCHEMBL630804

SCHEMBL630804

CC(O)c1cc(Cl)cc(C(F)(F)F)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 3/20 0.47
RAPGEF4 Q8WZA2 2/20 0.39
KLRK1 P26718 1/20 0.36
MICA Q29983 1/20 0.36
RAET1L Q5VY80 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
PNMT P11086 1/20 0.35
SLC13A3 Q8WWT9 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
GRN P28799 1/20 0.35
SORT1 Q99523 1/20 0.35
RHOC P08134 1/20 0.35
RHOA P61586 1/20 0.35
KRAS P01116 1/20 0.34
SOS1 Q07889 1/20 0.34
AHR P35869 1/20 0.34
CNR1 P21554 1/20 0.34
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL99424 0.86 PDE2A (0.46) PDE2APNMTALDH1A1PTPN5
SCHEMBL265045 0.86 PDE2A (0.46) PDE2APNMTALDH1A1PTPN5
SCHEMBL435108 0.86 PDE2A (0.46) PDE2APNMTALDH1A1PTPN5
SCHEMBL9967739 0.84 RAPGEF4 (0.41) PDE2ARAPGEF4KLRK1MICARAET1L
SCHEMBL9386794 0.82 PDE2A (0.43) PDE2APNMTALDH1A1PTPN5
SCHEMBL14321833 0.81 PDE2A (0.36) PDE2ARAPGEF4KLRK1MICARAET1L
SCHEMBL16959193 0.81 RAPGEF4 (0.39) PDE2ARAPGEF4KLRK1MICARAET1L
SCHEMBL17069226 0.81 RAPGEF4 (0.39) PDE2ARAPGEF4KLRK1MICARAET1L
SCHEMBL28672819 0.81 TACR1 (0.42) PDE2ARAPGEF4PNMTKRASSOS1
SCHEMBL17069227 0.81 RAPGEF4 (0.39) PDE2ARAPGEF4KLRK1MICARAET1L

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2419413-B1 DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES TAKEDA PHARMACEUTICAL (JP) 2016-11-23 EP disclosed
US-8853215-B2 Derivatives of N-acyl-N′-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-10-07 US disclosed
CN-102459209-A Derivatives of N-acyl-N' -phenylpiperazines for the prevention or treatment of diabetes (etc.) TAKEDA PHARMACEUTICAL 2012-05-16 CN disclosed
US-20120071489-A1 DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-22 US disclosed
EP-2419413-A1 DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES Takeda Pharmaceutical Company Limited (JP) 2012-02-22 EP disclosed
WO-2010119992-A1 DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071489-A1 DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES RBP4, RBP1, FABP4 PDE2A 3092/4885RAPGEF4 1475/4885KLRK1 4196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.